Core Viewpoint - Jiayou Bio-B (06998) has submitted a listing application to the Hong Kong Stock Exchange, marking the first reverse acquisition case of an innovative pharmaceutical company since the implementation of Rule 18A by the Hong Kong Stock Exchange [1] Group 1: Company Overview - Yiteng Pharmaceutical is a comprehensive professional biopharmaceutical company that has established a competitive and market-potential portfolio of original and innovative drugs through acquisitions of brand drug assets from multinational companies [1] - The product portfolio of Yiteng Pharmaceutical includes five main products, three of which are original products (Wenkexin, Xikelai, and Yirui Ping) and two innovative products (Vascepa and Mulpleta), all of which have been commercialized [1][2] Group 2: Financial Performance - Yiteng Pharmaceutical's revenue for the years ending December 31, 2022, 2023, and 2024 is projected to be 2.0738 billion, 2.3038 billion, and 2.5460 billion respectively, indicating steady sales growth driven by the strong performance and potential of its product portfolio [5] Group 3: Strategic Implications - The integration of Jiayou Bio's innovative R&D resources will enable Yiteng Pharmaceutical to accelerate the development and market promotion of innovative drugs, particularly the upcoming CDK4/6 inhibitor, which can synergize with Yiteng's existing HDAC inhibitor to explore broader market opportunities [5]

Core Insights - The oncology sector remains a hot area for innovative drug development, with significant unmet clinical needs driving pharmaceutical companies to invest in new treatments. In Q2 2024, 11 new anti-tumor drugs are expected to receive approval in China, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) [1]. Group 1: Drug Approvals and Regulatory Changes - The National Medical Products Administration (NMPA) has introduced expedited review processes for drug approvals, reducing the standard review time from 200 days to 130 days, and for urgently needed rare disease drugs from 200 days to 70 days [1]. - Among the 11 new drugs, three target the HER2 receptor, including Heng Rui Medicine's ADC, Zymeworks/Biocytogen's bispecific antibody, and Kelun-Biotech's ADC, each with different indications [2]. Group 2: Specific Drug Developments - Heng Rui Medicine's ADC, Rui Kang Qu Mo Zhu Dan, is the first domestic HER2 ADC for non-small cell lung cancer, with its application accepted on September 14, 2024, and recognized as a breakthrough therapy [2]. - Zymeworks' bispecific antibody, Zenida Mo Zhu Dan, received acceptance for its application on June 7, 2024, targeting HER2-positive cholangiocarcinoma, and was accelerated approved by the FDA in November 2024 [2]. - Kelun-Biotech's Bo Du Qu Mo Zhu Dan is expected to be approved for HER2-positive breast cancer treatment in Q2 2024, with its application accepted on May 11, 2023 [3]. Group 3: Other Notable Drug Candidates - Two new drugs for breast cancer and lymphoma are also expected to be approved, including G1 Therapeutics' oral CDK4/6 inhibitor for HR-positive, HER2-negative breast cancer and Xencor's monoclonal antibody for diffuse large B-cell lymphoma [4]. - The original drug Lomustine, used for Hodgkin's lymphoma and brain tumors, is set for its first domestic approval, with its application accepted on February 6, 2024 [5]. - Innovative drug Luwo Meitini from Fosun Pharma targets rare diseases and has two indications accepted for review in 2024 [6]. - The drug Suweisi Tanshu, a new generation anti-VEGF monoclonal antibody, aims to provide new treatment options for platinum-resistant ovarian cancer patients [6]. - The drug Golaileisi is expected to be approved for treating KRAS G12C mutation non-small cell lung cancer, with ongoing clinical trials for other solid tumors [6]. - Jikaxitini, a drug for myelofibrosis, is predicted to receive approval in Q2 2024, with its application accepted on October 17, 2022 [7].